Review Article

Coumarin: A Novel Tool for Multidisciplinary Activities

ABSTRACT
Coumarin 2H-1-benzopyran-2-one core has been a field of attention due to its exclusive propensity to accept variable classes of replacements which proves it as the origin for multi-disciplinary activities. Various review replicates that coumarin derivatives synthesized by structural modifications & alterations that exhibits activities like Anticancer, Carbonic Anhydrase Inhibition, Anti-bacterial, Antifungal, Antiviral, Anticoagulant, Anti Alzheimer activity, Anticonvulsant Activity, Anti-inflammatory etc. The motive of this study is to review, various substituted coumarin derivatives and provide the opportunity of designing & synthesizing novel coumarin based drugs and exploring their possible derivatives in the cure of numerous disorders.

KEYWORDS: Coumarin derivatives, Toxicity, Anti-Cancer, Carbonic Anhydrase Inhibition, Anti-bacterial, Anti-fungal.

INTRODUCTION
Coumarin belongs to their group term toward Coumarou, obtained from tonka beans; contain attached benzene (C6H6) as well as alpha-pyrene groups [1]. This denotes huge species of derivative that biologically originated from plants. Four chief Coumarin sub-classes contain (a) Simple Coumarins, (b) Furano-coumarins, (c) pyrano coumarins, as well as(d) Pyrone substituted Coumarins [2]. Some basic coumarins were the hydroxylated, alkoxylated, also alkylated products of parental drug. It includes derivatives of coumarin like 7-hydroxyl coumarin, also 6, 7- dihydroxy coumarin. Furano coumarins cover five membered furan rings committed to the coumarin core, separated into rectilinear or angular categories by replacement at single or both of the residual benzoid sites. [3] Pyrano coumarin parts are similar to furano coumarins however comprise a 6 membered ring. It includes units like Seselin as well as Xanthyletin coumarins replaced in the pyrone group contain 4-Hydroxycoumarin. [4] Coumarin exhibit antiviral as well as antibacterial activities. [5] Along with several anti-inflammatory capabilities [6] several coumarins have antioxidant activity rummaging super-oxide anion radicals [7, 8], decrease oedema in rat appendage carrageenan assessment as well as extra inflammatory sand rat representations. [9] Coumarin was initialy segregated in 1820 by scintist Vogel [10] as of tonka beans [Dipteryx odoranta Wild, Fabaceae family] also termed as Coumarou, a dialect French term. Afterward segregation, structural categorization (fig.1), synthesis, and genetical action of thousands of natural coumarins from plants, bacteria, fungi [11-13], as well as chemical synthesis [14] was done.
PHARMACOLOGICAL ACTIVITIES OF COUMARIN:

Anticancer Activity:
The word “cancer” describes a varied series of disorders produced by the accretion of alterations and categorized by a multistep procedure, including numerous diverse features which may not openly be the reason for cancer themselves nonetheless can rise the probabilities of genomic transformations.\(^{[15,16]}\) Lately, Maleki et al. require manufactured 18 O-prenylated coumarin products also verified this upon Hela Cervical Cancer also HDF usual cell units via MTT Assay\(^{[17]}\). Halawa et al. produced as well as categorized an innovative sequence of 4-arylamino-3-nitrocoumarin equivalents from 4-Hydroxycoumarin besides verified upon the individual cervix cancerous cellular space\(^{[18]}\). That compounds remained got towards the aim of human Topoisomerase-I compound, thus delaying in unit duplication besides leads toward cell demise.

Herrera et al. manufactured a sequence of 3 as well as7-styrlycoumarins, closely of which revealed anti proliferative action upon SW-480 individual colon adenocarcinoma cell units\(^{[19]}\). Between those,7-(4-Hydroxy-3, 5-dimethoxystyryl)-2H-chromen-2-one (Fig. 4) exhibited the maximum action, also this leads to cell-apoptosis in SW-480 cell units, possibly via moderating the tumour-suppressor protein (P-53). The novel derivatives were verified in-vivo, few compounds capable to suppress initial development for Colon Adeno-carcinoma\(^{[20]}\).

Carbonic Anhydrase Inhibition:
Carbonic anhydrase is universal metallo-enzymes which catalyse alterable hydration of CO2 into Bicarbonate buffer system. This enzyme was included within an extensive variety for biological also immunological procedures\(^{[21]}\) and derestricting by means of carbonic anhydrases inhibitors might exists valuable action for various diseases\(^{[22-25]}\). The model Carbonic anhydrase inhibitor might specifically show activity contrary to following iso-forms hCA IX, XII, for occurrence associated to some disorders\(^{[26, 27]}\). In 2019, 4-methylumbelliferone, Buran with colleagues manufactured, a sequel of eight substituted Coumarin dependent compounds having alkyl piperazine as well asaryl piperazine, and estimated their repressive action counter to isoforms hCA I, II, IX and XII\(^{[28]}\). Altogether verified drug which was capable for suppress isoform.
Compound with substitution at C-8 site for 4-Methylumbelliferone doesn’t have any effect happening on suppression. But substitution within the side chains of compounds shows increased activity. An analogous outcome was gone through numerous additional units which possess newly produced coumarin-dependent mixtures as well as estimate isoforms. Sulpho-cumarins, Bis-Coumarins along with coumarins 1, 3, 4-Oxadiazole spinoffs were certain samples [29-31].

**Antibacterial Activity:**
Multi-drug resistant bacteria are non-susceptible strains to more than one bacterial strain and are classified as enormously drug resistant strains. In 2005, more than 50 naturals as well as synthetic compounds were assisted and then estimated for structural activity relationship analysis. The antibacterial power of approximately 50 coumarin products, natural as well as synthetic, was assessed and then connected by a SAR analysis. Amongst the dynamic drugs, ostheno, exhibit maximum activity against S. aureus as well as B. cereus exhibited the maximum effective action with a MIC against S. aureus as well as B. cereus. In 2015, Nagamallu and colleagues demoralized the Vilsmeier-Haack reaction to get a sequence of novel pyrazole-holding coumarins as well as estimated their antioxidant along with antibacterial actions. In the middle of the series, two compounds (Y-R=CONH2 and Z-R=CSNH2) exhibited pharmacological activity. In 2018, Chavan and Hosamani projected a superficial process for the microwave assisted coumarin pyrazol derivatives and estimated their pharmacological action [36]. The investigators estimated in vitro antibacterial activity by agar plate diffusion method [37].

**Antifungal Activity:**
Fungal disorders are a familiar wave for animal as well as for human being also. Above 90% of all stated fungal related infections fit into one of the 4 types: Cryptococcus, Candida, Aspergillus and Pneumocystis. Coumarin products are able with antifungal action, possibly valuable in together pharmaceutical and food industry. Here infection, we will pay attention on the current developments in the advancement of new antifungal drugs aimed for human use. In spite of several classes of Candida can be a source of syndrome, [38, 41, 42]. In 2016, Shaik and co-workers planned an innovative sequence of coumarin derivatives coupled with other compounds, on the basis of a former effort by Shi and Zhou and of the communal usage of azoles as antifungal medicines. The anti-fungal strength of the new compounds existed verified counter to Candida albicans and additional fungous microorganisms [43]. Additionally, molecular docking studies exposed that these complexes have a high attraction in the direction of the active position of enzyme P450 cytochrome lanosterol 14a-demethylase. Coumarin based anti-fungal azoles have been further more examined by Elias and colleagues, in 2019, established a chain of 11 coumarins coupled by 1, 2, 4-triazole as well as imidazole [45-47].

**Antiviral Activity:**
Human past is aggrieved by the cyclical string of pandemic conditions and the study of novel antivirals is still enduring, because of the skill of viruses to alter their structure. Numerous compounds which show antiviral activity. Coumarins, similarly other poly-phenolic compounds, show an extra ordinary antiviral action. The antiviral activity of coumarins explains by means of different way which disturbs the lifecycle of viruses and their genetic actions might be altered dependent upon the mixture of several substituents with conjugates. Coumarins seem to be more effective on many viruses. Liu and
colleagues synthesized prenylated coumarins \(^{[58]}\) checked for their anti-inflammatory as well as anti-HIV activity. Cytopathic action of HIV-1 (EC50) and cytostatic action of C8166 cell line conferring to MTT assay \(^{[59, 60]}\). Three novel coumarin derivatives exhibited the greatest prohibition action of 0.29, 0.68 and 0.17 \(\mu\)M, individually.

Some of the probable benefits of oxidized coumarins might be their method of action in contradiction of viruses. Due to antioxidant action, coumarin derivatives might disturb intracellular redox-sensitive paths valuable for viral duplication \(^{[61]}\). As previously stated, coumarins used as anti-hepatitis agents. Tsay and colleagues examined the action in contrast to Hepatitis C Virus (HCV) of certain unusual imidazole-coumarin compounds \(^{[62]}\). Huang and colleagues attentive on the investigation of the potency stated by esculetin or (6,7-dihydroxycoumarin) against Hepatitis B Virus (HBV) \(^{[63]}\). Here we concluded that esculetin proficiently obstructs Hepatitis B Virus (HBV) repetition equally in vitro also in vivo, which delivers a chance for more advancement of the drug by means of anti-viral drug.

**Anticoagulant Activity:**
The anticoagulant action of coumarins was recognized in 1920.Karl Link and Harold Campbell synthesized 3,3'-methylenebis (4-hydroxycoumarin), after some time, identified as dicoumarol \(^{[64-67]}\). In spite of efficiency in addition with the benefits of an oral treatment, warfarin is not lacking of side-effects used as effective anti-coagulant agent \(^{[68, 69]}\). Therefore, the study of new harmless and well-organized compounds of a novel Vit -K Antagonist (VKA), tecarfarin (ATI-5923), presently under advancement \(^{[70]}\). Subsequently, drug-drug or food-drug connections remain evaded, along with genetic changeability of CYP-450 scheme, provided that a steadier anticoagulation action associated to warfarin \(^{[71]}\). Albrecht et al., organized with the new stage one study of patients among serious Kidney disorders \(^{[72, 73]}\). Tecarfarin is a suitable replacement of Warfarin for oral treatment for thrombo-embolic disorder.

Montagut-Romans et al., in 2017 discovered substituted derivatives with substitution on C-3 site by incorporating an unsaturated series. \(^{[74]}\). The fundamental evidence existed the SAR report accomplished by Gebaur in 2007, show that the action of 4-hydroxycoumarin was improved only by structural alteration at C-3 site via isoprenyl substitution.

\[\text{Fig. 3: Structure of Tecarfin.}\]

**Anti-Alzheimer activity:**
Alzheimer's disease is a deteriorating disorder of the central nervous system (CNS) that is primarily known by advanced remembrance damage \(^{[75-77]}\). Nowadays about 47 million individuals existing along with dementia globally. By 2050, this figure will have amplified overhead 135 million. Dementia distress4 people out of 1000 at the age ranging from 60 to 64 years \(^{[78]}\). Triazolyl-tacrine-coumarin derivatives as acetyl cholinesterase inhibitors used in the treatment of Alzheimer disease \(^{[79]}\).

**Anticonvulsant activity:**
Epilepsy is a common neurological disease, categorized by episodic also random attacks, including convulsions or temporary behavioural fluctuations. Its pathogenesis has not been totally explained yet. \(^{[80-84]}\).
At this point, we report some current developments in the usage of coumarins by way of anticonvulsant drugs. Abd-Allah and colleagues freshly calculated the anticonvulsant action of a sequence of coumarin products, attained by integration two or extra pharmacophoric supports in series to produce novel biochemical units using an enhanced biotic action \[85\].

The compounds now defined have all the essential fundamentals to use antiepileptic/ Anticonvulsant action: a lipotropic aryl group, the H-bonding field in addition with an electron-donor group. A like divalent medication method was tracked by Mohammadi-Khanaposhtani and colleagues, who manufactured a succession of coumarin-1,2,4-oxadiazole offshoots in order to make an innovative biochemical unit with better anticonvulsant outline than coumarin.

**Antinflammatory activity:**

Inflammation is a chief self-protective action of existing tissue to several injury causes, such as biotic pathogens, noxious chemicals, irritations as well as other injurious provocations \[89,94\]. As a complicated biological in addition physiological procedure, inflammation is branded by 5 chief sign and indications, together with puffiness, soreness, warmth, discomfort and local disfunction \[98\]. Infection, it is a defensive immune reply and is generally valuable. Though, persistent and overblown inflammation will help tissue injury and be the reason for diseases, for example, Arthritis, Sepsis, Atherosclerosis, and also even sarcoma. \[96-98\]. approximately some coumarins with diverse pharmacophores at C3 site must estimate for Antinflammatory actions. \[99-102\] Sulfone along with sulfoxide products covering heterocyclic fractions fit in to a significant type of energetic compounds having various biotic activities. \[103-104\]. It has been stated that the mixture of different pharmacophores in the equivalent structure is very possible to gain compounds with noteworthy action. Therefore, so as to advance innovative anti-inflammatory mediators, benzyl sulfone/sulfoxide groups was presented at C3 site of coumarin basic skeleton then aim complexes, 3-replaced coumarin products was constructed also produced.

![Fig. 4: The proposal of 3-substituted coumarin spinoffs.](image)

| Structure | Biological Activity | Molecular Target | Origin | Reference |
|-----------|---------------------|------------------|--------|-----------|
|           |                     |                  |        |           |
| ![Chemical Structure](image) | Anticancer | Carbonic Anhydrase IX and XII | Synthetic | [28] |
| ![Chemical Structure](image) | Antibacterial/Antifungal | S. aureus, E. coli, P. aeruginosa, A. Niger, A. flavus, C. albicans | Synthetic | [35] |
| ![Chemical Structure](image) | Antibacterial | S. aureus | Synthetic | [36] |
| ![Chemical Structure](image) | Antifungal | Several Candida strains-mode of action involving CYP51 and additional unidentified mechanism | Synthetic | [45] |
| Chemical Structure | Biological Activity | Indication | Source | Reference |
|--------------------|---------------------|------------|--------|-----------|
| ![Chemical Structure](image1.png) | Antiviral | Anti-HIV reverse transcriptase | Natural | [58] |
| ![Chemical Structure](image2.png) | Antiviral | Hepatitis C virus | Synthetic | [62] |
| ![Chemical Structure](image3.png) | Antiviral | Hepatitis B virus | Natural | [63] |
| ![Chemical Structure](image4.png) | Anticoagulant | murine VKORC1 inhibitor | Synthetic | [74] |
| ![Chemical Structure](image5.png) | Anticancer | - | Synthetic | [106] |
| ![Chemical Structure](image6.png) | Anticancer | STAT3 | Synthetic | [107] |
| ![Chemical Structure](image7.png) | Anticancer | Carbonic Anhydrase IX and XII | Natural | [108] |
| Compound | Type      | Activity                                      | Source    | Reference |
|----------|-----------|-----------------------------------------------|-----------|-----------|
|          | Antibacterial | S. Aureus, E. faecalis, E. coli               | Synthetic | [109]     |
|          | Antifungal  | C. albicans-ergosterol biosynthesis by lanosterol 14α-demethylase | Synthetic | [110]     |
|          | Antifungal  | C. albicans-antibiofilm                       | Natural   | [111]     |
|          | Antiviral   | HIV reverse transcriptase                      | Natural   | [112]     |
|          | Antiviral   | H1V1-IN                                       | Synthetic | [113]     |
|          | Anticoagulant | VKOR inhibitor                                | Synthetic | [114]     |
Anticoagulant | n.g. | Synthetic | [115]

Anti-Alzheimer | AChE, BuChE | Synthetic | [116]

Anticonvulsant | BDZ receptor | synthetic | [117]

Anti-inflammatory | NF-kB signalling pathways | synthetic | [118]

Toxicity of Coumarins:
For human lives, coumarin part takes a minor poisonous outcome. The primary dose, to the amount of four grams, shows the sign and symptoms of sickness also weakness. It has no fixed harmful outcome taking place in the heart; it slows the sense of the sympathetic nerves as well as paralyses the smooth muscles. Dihydrocoumarin, o-hydroxyphenyl propyl alcohol, as well as chroman have a sedative property. It is projected that the normal Western food may comprise about 1g/day of benzopyrones, mainly coumarins in addition with flavonoids. Therefore, wide-ranging study going on the genetical, pharmacological, as well as toxicological assets of coumarins has been passed out. Metabolic rate as well as toxicity analyses has been revised. Since inspections on the security used for human beings of coumarins current in foods, as well as in perfumes for beautifying usage. On the other hand, other documents theme out several important poisonousness of coumarin as well as certain coumarin derivatives. Actually, hepatotoxic properties have been seen in hepatocytes of various types, together with human being. In another exciting document, it has been showed that cytotoxic properties of coumarins are metabolism along with species-dependent, and as importance, rat models can’t be used to estimate a probable toxicity of coumarin in human beings. Certainly, an in-vitro dynamic study of o-HPA development in humanoid liver microsomes, recommended that human beings are not likely to show toxicologically applicable concentrations percentage of this metabolite, coming from the very-sensitive 3, 4-coumarin epoxide in addition with 3-hydroxycoumarin, for the reason that of the comparatively small dose of coumarin contacts. Recent studies in zebrafish embryos advised for coumarin also warfarin teratogen have lethal effects, but then at higher doses. Developing harmfulness
was appealed for coumarin and hydroxycoumarins. Remarkably, current studies established human being data showed a Tolerable Dose Intake (TDI) of coumarin equivalent to 0.1 mg/kg of body. This amount necessity not be crossed to evade toxic action. Undeniably, through Christmas time of year in Germany, the eating of cassia cinnamon has led to in a higher dosage that the TDI of coumarin was regularly touched, therefore raising the danger for hepatotoxic as well as carcinogenic properties \(^{127}\).

**CONCLUSION:**
Coumarin derivatives have acknowledged growing consideration for their varied genetical and pharmacological actions. In this review, we tried to cover work associated with structural modifications that gives significant pharmacological actions related to coumarins (antiviral, carbonic anhydrase inhibition, antioxidant, antibacterial, anti-inflammatory, anticonvulsant, antifungal, anti-neurodegenerative, anticoagulant). This review is of great importance for the proposal and enhancement of the coumarin derivatives as novel principal molecules for various disease therapies. It is our expectancy that this review will help for future synthesis and development of coumarin possible activities.

**REFERENCES:**

1. Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. Second Edition, Hampshire UK, Intercept Ltd: 1999; 263-7.
2. Jain PK and Joshi H. Coumarin: chemical and pharmacological profile. Journal of Applied Pharmaceutical Science; 2012; 2(6): 236-40.
3. Ojala T. PhD Thesis, University of Helsinki, Helsinki, Finland:2001; 95-06.
4. Esra kupeli Akkol, Yasin Genc; Busra Karpuz, Eduardo Sobarzo-Sanchez, Raffaele Capasso. Coumarins and coumarin-related compounds in pharmacotherapy of cancer, Cancers; 2020; 12:1959.
5. Siddiqui AA, Rajesh R, Alagarsamy V and De Clercq E. Synthesis, antiviral, antituberculous, and antibacterial activities of some novel, 4-(4-substituted phenyl)-6-(4-nitrophenyl)-2- (substituted imino) pyrimidines. Arch Pharm (Weinheim); 2007; 340: 95-02.
6. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE and Nicolaides DN. Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. Curr Pharm Des; 2004; 10: 3813-33.
7. Fylaktakidou KC, Hadjipavlou-Litina DJ. Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities, Curr. Pharm Des; 2004; 10(30):3813-33.
8. Kontogiorgis CA, Savvoglou K, Hadjipavlou-Litina DJ. Antiinflammatory and antioxidant evaluation of novel coumarin derivatives. J Enzymes Inhib Med Chem. 2006; 21(1):21-9.
9. Cong HH, Khaziakhmetova VN, Zigashina LE. Rat paw oedema modelling and NSAIDSs, Timing of effects, Int J Risk Saf Med, 27Suppl. 2015; 1: S76-7.
10. Ahmed A, Al-Amiery. Yasameen K, Al-Majeda,[... Abu Bakar Mohamad. Novel macromolecules derived from coumarin: synthesis and antioxidant activity; Scientific Reports 2015; 5 :11825.
11. Maria Joao Matos, Lourdes Santana, Eugenio Uriarte, Orlando A. Abreu, Enrique Molina and Estela Guardado Yordi. Coumarin- An Important class of phytochemicals; Phytochemicals- Isolation, Charactrisation and Role in Human Health, 2015; 113-140.
12. Maria João Matos, Lourdes Santana, Eugenio Uriarte, Orlando A. Abreu, Enrique Molina and Estela Guardado Yordi. Coumarins: An Important class of phytochemicals; Phytochemicals- Isolation, Characterisation and Role in Human Health, 2015; 113-140.

13. Costa TM, Tavares LBB, de Olivera D. Fungi as a source of natural coumarins production. Appl Microbiol Biotechnol ; 2016; 100(15): 6571-6584.

14. F. Borges, F. Roleira, N. Milhazes, L. Santana and E. Uriarte. Simple Coumarins and Analogous in Medicinal Chemistry: Occurrence, Synthesis and Biological Activity; Current Medicinal Chemistry, 2005; 12, 887-916.

15. Pierce, B.A. Genetics. A Conceptual Approach, 3rd ed.; W. H. Freeman and Company: New York, NY, USA 2010.

16. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000; 100, 57–70.

17. Maleki, E.H.; Bahrami, A.R.; Sadeghian, H.; Matin, M.M. Discovering the structure–activity relationships of different O-prenylated coumarin derivatives as effective anticancer agents in human cervical cancer cells. Toxicol. In Vitro, 2020; 63, 104-745.

18. Halawa, A.H.; Eliwa, E.M.; Hassan, A.A.; Nassar, H.S.; El-Eisawy, R.A.; Ismail, M.; Frese, M.; Shaaban, M.; El-Agody, A.M.; Bedair, A.H.; et al. Synthesis, in vitro cytotoxicity activity against the human cervix carcinoma cell line and in silico computational predictions of new 4-arylamino-3-nitrocoumarin analogues. J. Mol. Struct., 2020; 1200, 127047.
carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma. Bioorg. Chem., 2019; 87, 838–850.

31. Narella, S.G.; Shaik, M.G.; Mohammed, A.; Alvala, M.; Angeli, A.; Supuran, C.T. Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg. Chem., 2019; 87, 765–772.

32. Bassetti, M.; Merelli, M.; Temperoni, C.; Astilean, A. New antibiotics for bad bugs: Where are we? Ann. Clin. Microbiol. Antimicrob., 2013; 12, 1–15.

33. Brown, E.D.; Wright, G.D. Antibacterial drug discovery in the resistance era. Nature, 2016; 529, 336–343.

34. De Souza, S.M.; Delle Monache, F.; Smânia, A. Antibacterial activity of coumarins. Z. Naturforsch. Sect. C J. Biosci., 2005; 60, 693–700.

35. Nagamallu, R.; Srinivasan, B.; Ningappa, M.B.; Kariyappa, A.K. Synthesis of novel coumarin appended bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities, Bioorg. Med. Chem. Lett. 2016; 26, 690–694.

36. Chavan, R.R.; Hosamani, K.M. Microwave-assisted synthesis, computational studies and antibacterial/anti-inflammatory activities of compounds based on coumarin-pyrazole hybrid: R. Soc. Open Sci., 2018; 5.

37. Rahman, A.; Choudhary, M.I.; Thomsen, W.J. Bioassay Techniques for Drug Development, 1st ed.; Harwood Academic Publishers: Amsterdam, The Netherlands, 2001.

38. Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med., 2012; 4, 1–10.

39. GAFFI Fungal Disease Frequency|Gaffi—Global Action Fund for Fungal Infections. Available online: https://www.gaffi.org/why/fungal-disease-frequency/ (accessed on 21 March 2020).

40. How Common are Fungal Diseases?—Fungal Infection Trust. Available online: https://www.Fungalinfectiontrust.org/how-common-are-fungal-diseases (accessed on 21 March 2020).

41. Bartlett, J.G. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Infect. Dis. Clin. Pract., 2004; 12, 376.

42. Pfaffer, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev., 2007; 20, 133–163.

43. Shi, Y.; Zhou, C.H. Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents. Bioorg. Med. Chem. Lett., 2011; 21, 956–960.

44. Shaikh, M.H.; Subhedar, D.D.; Kalam Khan, F.A.; Sangshetti, J.N.; Shingate, B.B. 1,2,3-Triazole incorporated coumarin derivatives as potential antifungal and antioxidant agents. Chin. Chem. Lett., 2016; 27, 295–301.

45. Elias, R.; Benhamou, R.I.; Jaber, O.Z.; Dorot, O.; Zada, S.L.; Oved, K.; Pichinuk, E.; Fridman, M. Antifungal activity, mode of action variability and subcellular distribution of coumarin-based antifungal azoles. Eur. J. Med. Chem., 2019; 179, 779–790.

46. Lee, J.H.; Kim, Y.G.; Cho, H.S.; Ryu, S.Y.; Cho, M.H.; Lee, J. Coumarins reduce biofilm formation and the virulence of Escherichia coli O157:H7. Phytomedicine, 2014; 21, 1037–1042.

47. Reen, F.J.; Gutiérrez-Barranquero, J.A.; Parages, M.L.; O’Gara, F. Coumarin: A novel player in microbial quorum sensing and biofilm formation inhibition. Appl. Microbiol. Biotechnol., 2018; 102, 2063–2073.

48. WHO Corona virus (COVID-19) Events as They Happen. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed on 21 March 2020).

49. Mishra, S.; Pandey, A.; Manvati, S. Coumarin: An emerging antiviral agent. Heliyon, 2020; 6, 32-17.

50. Lilly Ganju, S.S. Plant Derived Antivirals: A Potential Source of Drug Development. J. Virol. Antivir. Res., 2013; 2.
51. Kwon, J.E.; Lee, Y.G.; Kang, J.H.; Bai, Y.F.; Jeong, Y.J.; Baek, N.I.; Seo, Y.J.; Kang, S.C. Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture. Bioorg. Chem., 2019; 93, 103-320.

52. Guo, H.; Wan, X.; Niu, F.; Sun, J.; Shi, C.; Ye, J.M.; Zhou, C. Evaluation of antiviral effect and toxicity of total flavonoids extracted from Robinia pseudoacacia cv. idaho. Biomed. Pharmacother., 2019; 118, 109-335.

53. Dewi, B.E.; Ratningpoeti, E.; Desti, H.; Angelina, M. In vitro and in silico study to evaluate the effectiveness of quercitrin as antiviral drug to dengue virus. AIP Conf. Proc., 2019; 21-93.

54. Sahuc, M.; Sahli, R.; Rivière, C.; Pène, V.; Lavie, M. Vandeputte, Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J. Virol. 2019; 93, 1–15.

55. Teplova, V.V.; Isakova, E.P.; Klein, O.I.; Dergachova, D.I.; Gessler, N.N.; Deryabina, Y.I. Natural Polyphenols: Biological Activity, Pharmacological Potential, Means of Metabolic Engineering (Review). Appl. Biochem. Microbiol., 2018; 54, 221–237.

56. Campagna, M.; Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans., 2010; 38, 50–53.

57. Hassan, M.Z.; Osman, H.; Ali, M.A.; Ahsan, M.J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem., 2016; 123, 236–255.

58. Liu, Y.P.; Yan, G.; Xie, Y.T.; Lin, T.C.; Zhang, W.; Li, J.; Wu, Y.J.; Zhou, J.Y.; Fu, Y.H. Bioactive prenylated coumarins as potential anti-inflammatory and anti-HIV agents from Clausena lenis. Bioorg. Chem., 2020; 97, 103-699.

59. Liu, Y.P.; Liu, Q.L.; Zhang, X.L.; Niu, H.Y.; Guan, C.Y.; Sun, F.K.; Xu, W.; Fu, Y.H., Bioactive monoterpenoid indole alkaloids from Nauclea officinalis. Bioorg. Chem., 2019; 83, 1–5.

60. Liu, Y.P.; Zhao, W.H.; Feng, X.Y.; Zhang, Z.J.; Zong, K.; Sun, Z.G.; Zheng, Y.T.; Fu, Y.H. Novel tetrahydrofuran derivates from Trigonostemon howii with their potential anti-HIV-1 activities. Bioorg. Chem., 2018; 79, 111–114.

61. Bizzarri, B.M.; Botta, L.; Capecchi, E.; Celestino, I.; Checconi, P.; Palamara, A.T.; Nencioni, L.; Saladino, R. Regioselective IBX-Mediated Synthesis of Coumarin Derivatives with Antioxidant and Anti-influenza Activities. J. Nat. Prod., 2017; 80, 3247–3254.

62. Tsay, S.C.; Lin, S.Y.; Huang, W.C.; Hsu, M.H.; Hwang, K.C.; Lin, C.C.; Horng, J.C.; Chen, I.C.; Hwu, J.R.; Shieh, F.K.; et al. Synthesis and structure-activity relationships of imidazole-coumarin conjugates against hepatitis C virus. Molecules, 2016; 21, 228.

63. Huang, S.X.; Mou, J.F.; Luo, Q.; Mo, Q.H.; Zhou, X.L.; Huang, X.; Xu, Q.; Tan, X.D.; Chen, X.; Liang, C.Q. Anti-Hepatitis B Virus Activity of Esculetin from Microsorium fortunei in Vitro and in Vivo. Molecules, 2019; 24, 3475.

64. Wardrop, D.; Keeling, D. The story of the discovery of heparin and warfarin. Br. J. Haematol., 2008; 141, 757–763.

65. Wadelius, M.; Pirmohamed, M. Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogen. J., 2007; 7, 99–111.

66. Kamali, F.; Pirmohamed, M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br. J. Clin. Pharmacol., 2006; 61, 746–751.

67. Pirmohamed, M. Warfarin: Almost 60 years old and still causing problems. Br. J. Clin. Pharmacol., 2006; 62, 509–511.

68. Grillot, A. Acenocoumarol in Thromboembolic Disorders. Cardiovasc. Pharmacol. Open Access, 4; 2015.

69. Lippi, G.; Gosselin, R.; Favaloro, E.J. Current and Emerging Direct Oral Anticoagulants: State-of-the-Art. Semin. Thromb. Hemost., 2019; 45, 490–500.

70. Székely, O.; Miyazawa, K.; Lip, G.Y.H. (2018). Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. Expert Opin. Pharmacother., 2018; 19, 1999–2009.
71. Bavisotto, L.M.; Ellis, D.J.; Milner, P.G.; Combs, D.L.; Irwin, I.; Canafax, D.M. (2011). Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J. Clin. Pharmacol., 2011; 51, 561–574.
72. Albrecht, D.; Ellis, D.; Canafax, D.M.; Combs, D.; Druzgala, P.; Milner, P.G.; Midei, M.G. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Thromb. Haemost., 2017; 117, 706–717.
73. Albrecht, D.; Turakhia, M.P.; Ries, D.; Marbury, T.; Smith, W.; Dillon, D.; Milner, P.G.; Midei, M.G. Pharmacokinetics of tecarfarin and warfarin in patients with severe chronic kidney disease. Thromb. Haemost. 2017; 117, 2026–2033.
74. Montagut-Romans, A.; Boullven, M.; Jacolot, M.; Moebs-Sanchez, S.; Hascoet, C.; Hammad, A.; Besse, S.; Lemaire, M.; Benoit, E.; Lattard, V.; et al. Synthesis and biological evaluation of C-3 aliphatic coumarins as vitamin K antagonists. Bioorg. Med. Chem. Lett. 2017; 27, 1598–1601.
75. Gebauer, M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg. Med. Chem. 2007; 15, 2414–2420.
76. Camps P, El Achab R, Morral J, et al. New tacrine-huperzine a hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer’s disease. J Med Chem; 2000; 43:4657–66.
77. Sippl W, Contreras JM, Parrot I, et al. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J Comput-Aided Mol Des; 2001; 15:395–410.
78. Czarnecka K, Girek M, Maciejewska K, et al. New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem; 2018; 33:158–70.
79. Dong C, Wang G, H, et al. Design, Synthesis and Pharmacological capacities for the treatment of Alzheimer’s disease. J Enzyme Inhib Med Chem; 2018; 33:158–70.
80. Kamelia M. Amin, Doaa E. Abdel Rahma, Yasmin A. Al-Eryani; Synthesis and preliminary evaluation of some substituted coumarins as anticonvulsant agents; Bioorganic and Medicinal chemistry Volume 16, Issue 10; 2008; 5377-5388.
81. Aboul-Enein, M.N.; El-Azzouny, A.A.; Attia, M.I.; Maklad, Y.A.; Aboutabl, M.E.; Ragab, F.; El-Hamid, W.H.A.A. Anticonvulsant profiles of certain new 5-Aryl-9-substituted6,9-diazaspiro- [4.5] decane-8,10-dionesand1-Aryl-4-substituted-1,4-diazaspiro [5.5] undecane-3,5-diones. Int. J. Mol. Sci., 2014; 15, 16911–16935.
82. Kamin’ski, K.; Rapacz, A.; Łuszczyk, J.J.; Latacz, G.; Obniska, J.; Kiec’-Kọnonowicz, K.; Filippek, B. Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl) propanamide and 2-(2,5-dioxopyrrolidin-1-yl) butanamide derivatives. Bioorg. Med. Chem., 2015; 23, 2548–2561.
83. Abd-Allah, W.H.; Aboutabl, M.E.; Aboul-Enein, M.N.; El-Azzouny, A.A.S. Synthesis, molecular modeling studies and anticonvulsant activity of certain 1-(benzyl (aryl) amino) cyclohexyl) methyl esters. Bioorg. Med. Chem., 2017; 71, 135–145.
84. Sahu, M.; Siddiqui, N.; Naim, M.J.; Alam, O.; Yar, M.S.; Sharma, V.; Wakode, S. Design, Synthesis and Docking Study of Pyrimidine–Tria
85. Abd-Allah, W.H.; Osman, E.E.A.; Anwar, M.A.E.M.; Attia, H.N.; El Moghazy, S.M. Design, synthesis and docking studies of novel benzopyrone derivatives as anticonvulsants. Bioorg. Chem., 2020; 98, 103-738.
86. Aboutabl, M.E.; Hassan, R.M.; El-Azzouny, A.A.S.; Aboul-Enein, M.N.; Abd-Allah, W.H. Design and synthesis of novel parabanic acid derivatives as anticonvulsants. Bioorg. Chem., 2020; 94, 103473.
87. Partap, S.; Yar, M.S.; Hassan, M.Z.; Akhtar, M.J.; Siddiqui, A.A. Design, Synthesis and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents. Arch. Pharm., 2017; 350, 1–14.
88 Mohammadi-Khanaposhtani, M.; Ahangar, N.; Sobhani, S.; Masahi, P.H.; Shakiba, A.; Saeedi, M.; Akbarzadeh, T. Design, synthesis, in vivo and in silico evaluation of new coumarin-1,2,4-oxadiazole hybrids as anticonvulsant agents. Bioorg. Chem., 2019; 89, 102-989.
89. Ahangar, N.; Ayati, A.; Alipour, E.; Pashapour, A.; Foroumadi, A.; Emami, S. 1-[(2-aryltiazol-4-yl) methyl] azoles as a new class of anticonvulsants: Design, synthesis, in vivo screening and in silico drug-like properties. Chem. Biol. Drug Des., 2011; 78, 844–852.
90. Lankau, H.J.; Unverferth, K.; Grunwald, C.; Hartenhauer, H.; Heinecke, K.; Bernöster, K.; Dost, R.; Egerland, U.; Rundfeldt, C. New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity. Eur. J. Med. Chem., 2007; 42, 873–879.
91. Faizi, M.; Sheikhhia, M.; Ahangar, N.; Ghomi, H.T.; Shafaghi, B.; Shafiee, A.; Tabatabai, S.A. Design, synthesis and pharmacological evaluation of novel 2-[(2-Chlorophenoxy) phenyl]-1,3,4-oxadiazole derivatives as benzodiazepine receptor agonists. Iran. J. Pharm. Res., 2012; 11, 83–90.
92. Mohammadi-Khanaposhtani, M.; Shabani, M.; Faizi, M.; Aghaei, I.; Jahani, R.; Sharafi, Z.; Shamsaei Zafarghandi, N.; Mahdavi, M.; Akbarzadeh, T.; Emami, S.; et al. Design, synthesis, pharmacological evaluation and docking study of new acridone derivatives as benzodiazepine receptor agonists. Eur. J. Med. Chem., 2016; 112, 91–98.
93. Lamkanfi, M.; Dixit, V. M., Cell, 2014; 157, 1013–1022.
94. Guo, H.; Callaway, J. B., Ting, J. P., Nat. Med., 2015; 21, 677–687.
95. Silva Y. K. C. D., Augusto C. V., Barbosa M. L. D. C., Melo G. M. D. A., Queiroz A. C. D., Dias T. D. L. M., Júnior W. B., Barreiro E. J., Lima L. M., Alexandre-Moreira M. S., Bioorgan. Med. Chem., 2010;18, 5007-5015.
96. Kux K., Pitsouli C., Front. Cell. Infect. Mi., 2014; 4, 49 .
97. Zhang L., Yang L., Molecules, 2019, 24, 3632-3640.
98. Melagraki G., Afantitis A., Iggleissi-Markopoulou O., Detsi A., Koufaki M., Kontogiorgis C., Hadjipavlou-Litina D.J., Eur. J. Med. Chem., 2009; 44, 3020-3026.
99. Diao, Q.P.; Guo, H.; Wang, G.Q. Design, Synthesis and In Vitro Anticancer Activities of Diethylene Glycol Tethered Isatin-1,2,3-triazole-coumarin Hybrids. J. Heterocycl. Chem., 2019; 56, 1667–1671.
100. Cai, G.; Yu, W.; Song, D.; Zhang, W.; Guo, J.; Zhu, J.; Ren, Y.; Kong, L. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors. Eur. J. Med. Chem., 2019; 174, 236–251.
101. Folis, B.; Distinto, S.; Meleddu, R.; Deplano, S.; Maccioni, E.; Floris, C.; Rosa, A.; Nieddu, M.; Caboni, P.; Sissi, C.; et al. Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic anhydrases IX and XII: Isolation, biological studies and in silico evaluation. J. Enzyme Inhib. Med. Chem., 2020; 35, 539–548.
102. Chougala, B.M.; Samundeeswari, S.; Holiyachi, M.; Naik, N.S.; Shastri, L.A.; Dodamani, S.; Jalalpure, S.; Dixit, S.R.; Joshi, S.D.; Sunagar, V.A. Green, unexpected synthesis of bis-coumarin derivatives as potent anti-bacterial and anti-inflammatory agents. Eur. J. Med. Chem., 2018;143, 1744–1756.
110. Tiwari, S.; Seijas, J.; Vazquez-Tato, M.; Sarkate, A.; Kamik, N.; Nikalje, A. Facile Synthesis of Novel Coumarin Derivatives, Antimicrobial Analysis, Enzyme Assay, Docking Study, ADME/Toxicity. Molecules. 2017; 22, 11-72.

111. Xu, K.; Wang, J.L.; Chu, M.P.; Jia, C. Activity of coumarin against Candida albicans biofilms. J. Mycol. Med. 2019; 29, 28–34.

112. Liu, Y.P.; Yan, G.; Guo, J.M.; Liu, Y.Y.; Li, Y.J.; Zhou, B.J.; Lehman, A. Coumarin Conjugates. J. Mycol. Med. 2019; 34, 631–637.

113. Jesumoroti, O.J.; Faridoon; Mnkandhla, D.; Isaacs, M.; Hoppe, H.C.; Klein, R. Evaluation of novel N0-(3-hydroxybenzoyl)-2-oxo-2H-chromene-3-carbohydrazide derivatives as potential HIV-1 integrase inhibitors. Medchemcomm. 2019; 10, 80–88.

114. Székely, O.; Miyazawa, K.; Lip, G.Y.H. Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. Expert Opin. Pharmacother., 2018; 19, 1999–2009.

115. Bang, N.C.; Abysev, A.Z.; Ivkin, D.Y. Synthesis and In Vivo Evaluation of New Coumarin Conjugates as Potential Indirect-Action Anticoagulants. Pharm. Chem. J., 2019; 53, 419–422.

116. De Souza, G.A.; da Silva, S.J.; de Nigris Del Cistia, C.; Pitasse-Santos, P.; de Oliveira Pires, L.; Passos, Y.M.; Cordeiro, Y.; Cardoso, C.M.; Castro, R.N.; Sant'Anna, C.M.R.; et al. Discovery of novel dual-active 3-(4-(dimethylamino)phenyl)-7-aminoalcoxy-coumarin as potent and selective acetylcholinesterase inhibitor and antioxidant. J. Enzyme Inhib. Med. Chem., 2019; 34, 631–637.

117. Mohammadi-Khanaposhtani, M.; Ahangar, N.; Sobhani, S.; Mashi, P.H.; Shakiba, A.; Saeedi, M.; Akbarzadeh, T. Design, synthesis, in vivo and in silico evaluation of new coumarin-1,2,4-oxadiazole hybrids as anticonvulsant agents. Bioorg. Chem., 2019; 89, 102989.

118. Mu, C.; Wu, M.; Li, Z. Anti-Inflammatory Effect of Novel 7-Substituted Coumarin Derivatives through Inhibition of NF-κB Signaling Pathway. Chem. Biodivers., 2019; 16, 180-0559.

119. Angela Stefanchi, Francesco Leonetti, and Angelo Carotti; Coumarin: A Natural, Privileged and Versatile Scaffold for bioactive compounds; Molecules; 2018; 23(2): 250.

120. Lacy, A.; O'Kennedy, R. Studies on coumarines and coumarin related compounds to determine their therapeutic role in the treatment of cancer. Curr. Pharm. Des., 2004; 10, 3797–3811.

121. Edwards, A.J., Price R.J.; Renwick, A.B., Lake, B.G. Lack of effect of coumarin on unscheduled DNA synthesis in the in vivo rat hepatocyte DNA repair assay. Food and chemical toxicology, 2000; 38(5); 403-409.

122. Tanaka, Y.; Fujii, W.; Hori, H.; Kitagawa, Y.; Ozaki, K. Relationship between coumarin-induced hepatocellular toxicity and mitochondrial function in rats. Food Chem. Toxicol., 2016; 90, 1–9.

123. Farinola, N., & Pillar, N.B. CYP2A6 Polymorphisms: is there a role for pharmacogenomics in preventing coumarin induced hepatotoxicity in lymphedema patients? Pharmacogenomics, 2007; 8(2): 151-158.

124. Rietjens, I . M. C., Boersma, M. G., Zaleska, M., & Punt A.; Differences in stimulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modelling; Toxicology in vitro, 2008; 22(8): 1890-1901.

125. Born, S.L.; Caudill, D.; Smith, B.J.; Lehman-McKeeman, L.D. In vitro kinetics of coumarin 3, 4-epoxidation: Application to species differences in toxicity and carcinogenicity. Toxicol. Sci., 2000; 58, 23–31.

126. Weigta, S.; Hueblera, N.; Streckerb, R.; Braunbeckb, T.; Broschardc, T.H. Developmental effects of coumarin and the anticoagulant coumarin derivative warfarin on zebrafish (Danio rerio) embryos. Reprod. Toxicol. 2012; 33. 133–141.

127. Abraham, K.; Woehrlin, F.; Lindtner, O.; Heinemeyer, G.; Lampen, A. Toxicology and risk assessment of coumarin: Focus on human data. Mol. Nutr. Food Res. 2010; 54, 228–239.
